Intarcia Therapeutics

Intarcia Therapeutics Overview

Founded 1995
Founded
Status Private
Employees 240
Employees
Latest Deal Type Debt
Latest Deal Amount $200M
Latest Deal Amount
Investors 41

Intarcia Therapeutics General Information

Description

Developer of drug therapies intended to deliver an improved therapeutic outcome while enhancing patients' quality of life. The company's proprietary subcutaneous delivery system comprised of three unique technologies, including a stabilization technology that allows for proteins, peptides, antibody fragments and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more, providing patients with necessary treatment required for chronic serious disorders in the field of diabetes, obesity and autoimmune diseases.

Contact Information

Formerly Known As
BioMedicines
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • One Marina Park Drive
  • 13th Floor
  • Boston, MA 02210
  • United States
+1 (617) 000-0000

Intarcia Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intarcia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
23. Debt - General 10-Mar-2020 $200M 00.000 Completed Profitable
22. Later Stage VC 14-Jan-2020 00000 00.000 Completed Profitable
21. Debt - General 01-Mar-2019 0000 00.000 Completed Profitable
20. Later Stage VC (Series EE) 03-Aug-2017 00000 00.000 00.000 Completed Profitable
19. Later Stage VC (Series DD) 01-May-2017 00.000 Completed Profitable
18. Later Stage VC (Series CC) 27-May-2016 00000 00.000 Completed Profitable
17. Debt - General 06-May-2016 0000 00000 Completed Generating Revenue
16. Later Stage VC (Series DD) 27-Mar-2014 00000 00000 00.000 Completed Clinical Trials - Phase 3
15. Later Stage VC (Series B2) $435M Completed Clinical Trials - Phase 3
14. Later Stage VC (Series B1) $435M Completed Clinical Trials - Phase 3

Intarcia Therapeutics Cap Table

To view Intarcia Therapeutics‘s complete cap table, request access >>
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series EE 00,000,000 00.000000 00 000 000 00 000 00.000
Series DD 0,000,000 00.000000 00 000.00 000.00 00 000.00 0.000
Series CC 00,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series BB3 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series BB2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series BB1 3,833,865 $0.001000 8% $6 $6 1x $6 5.6%
Series AA 3,180,135 $0.001000 8% $6 $6 1x $6 4.64%

Intarcia Therapeutics Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
TC Biopharm Venture Capital-Backed Glasgow, United Kingdom 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
00 000000000000000 Formerly VC-backed Cambridge, MA 00 000.00 00000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00

Intarcia Therapeutics Executive Team (31)

Name Title Board Seat Contact Info
Kurt Graves Chairman, President & Chief Executive Officer
David Spellman Chief Financial Officer & Chief Business Officer
Raymond Keane JD Vice President, General Counsel & Chief Legal Officer
Jay Smith Chief Experience Officer
Thane Wettig Chief Commercial Officer

17 Former Executives

Intarcia Therapeutics Board Members (12)

To view Intarcia Therapeutics‘s full board member team, request access >>
Name Representing Role Since
Bryan Roberts Ph.D Venrock Board Member 000 0000
Gino Santini Self Board Member 000 0000
James Rosenthal JD Self Board Member 000 0000
Jay Skyler MD Self Board Member 000 0000
Kurt Graves Intarcia Therapeutics Chairman, President & Chief Executive Officer 000 0000

4 Former Board Members

Intarcia Therapeutics Investors (41)

To view Intarcia Therapeutics‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Baillie Gifford Asset Manager Minority 000 0000 000000 0
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
Cloudstone Capital Venture Capital Minority 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
Kayon Partners Venture Capital Minority 000 0000 000000 0

Intarcia Therapeutics Investments & Acquisitions (4)

To view Intarcia Therapeutics‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 24-Sep-2015 000000000000000000 Drug Discovery 0000 000000
000000000000 01-Apr-2003 00000 00000 00 000.00 Pharmaceuticals
000000000000 01-Nov-2000 00000 00000 00 0000 Pharmaceuticals
Cytokinetics 01-Aug-1999 Early Stage VC 0000 Pharmaceuticals

Ready to get started?

Request a free trial

Intarcia Therapeutics Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000 01-Apr-2003 00000 00000 00 000.00 Completed
  • 10 buyers
000000000000 01-Nov-2000 00000 00000 00 0000 Completed
  • 6 buyers
Cytokinetics 01-Aug-1999 Early Stage VC 0000 Completed
  • 4 buyers